Cargando…
Are we closer to having drugs to treat muscle wasting disease?
The two most common muscle wasting diseases in adults are sarcopenia and cachexia. Despite differences in their pathophysiology, it is believed that both conditions are likely to respond to drugs that increase muscle mass and muscle strength. The current gold standard in this regard is exercise trai...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053564/ https://www.ncbi.nlm.nih.gov/pubmed/24865381 http://dx.doi.org/10.1007/s13539-014-0149-7 |
_version_ | 1782320392932687872 |
---|---|
author | Morley, John E. von Haehling, Stephan Anker, Stefan D. |
author_facet | Morley, John E. von Haehling, Stephan Anker, Stefan D. |
author_sort | Morley, John E. |
collection | PubMed |
description | The two most common muscle wasting diseases in adults are sarcopenia and cachexia. Despite differences in their pathophysiology, it is believed that both conditions are likely to respond to drugs that increase muscle mass and muscle strength. The current gold standard in this regard is exercise training. This article provides an overview of candidate drugs to treat muscle wasting disease that are available or in development. Drugs highlighted here include ghrelin agonists, selective androgen receptor molecules, megestrol acetate, activin receptor antagonists, espindolol, and fast skeletal muscle troponin inhibitors. |
format | Online Article Text |
id | pubmed-4053564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-40535642014-06-12 Are we closer to having drugs to treat muscle wasting disease? Morley, John E. von Haehling, Stephan Anker, Stefan D. J Cachexia Sarcopenia Muscle Editorial The two most common muscle wasting diseases in adults are sarcopenia and cachexia. Despite differences in their pathophysiology, it is believed that both conditions are likely to respond to drugs that increase muscle mass and muscle strength. The current gold standard in this regard is exercise training. This article provides an overview of candidate drugs to treat muscle wasting disease that are available or in development. Drugs highlighted here include ghrelin agonists, selective androgen receptor molecules, megestrol acetate, activin receptor antagonists, espindolol, and fast skeletal muscle troponin inhibitors. Springer Berlin Heidelberg 2014-05-28 2014-06 /pmc/articles/PMC4053564/ /pubmed/24865381 http://dx.doi.org/10.1007/s13539-014-0149-7 Text en © Springer-Verlag Berlin Heidelberg 2014 |
spellingShingle | Editorial Morley, John E. von Haehling, Stephan Anker, Stefan D. Are we closer to having drugs to treat muscle wasting disease? |
title | Are we closer to having drugs to treat muscle wasting disease? |
title_full | Are we closer to having drugs to treat muscle wasting disease? |
title_fullStr | Are we closer to having drugs to treat muscle wasting disease? |
title_full_unstemmed | Are we closer to having drugs to treat muscle wasting disease? |
title_short | Are we closer to having drugs to treat muscle wasting disease? |
title_sort | are we closer to having drugs to treat muscle wasting disease? |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053564/ https://www.ncbi.nlm.nih.gov/pubmed/24865381 http://dx.doi.org/10.1007/s13539-014-0149-7 |
work_keys_str_mv | AT morleyjohne areweclosertohavingdrugstotreatmusclewastingdisease AT vonhaehlingstephan areweclosertohavingdrugstotreatmusclewastingdisease AT ankerstefand areweclosertohavingdrugstotreatmusclewastingdisease |